Khisimuzi Mdluli

Summary

Affiliation: Global Alliance for TB Drug Development
Country: USA

Publications

  1. ncbi Novel targets for tuberculosis drug discovery
    Khisimuzi Mdluli
    Global Alliance for TB Drug Development, 80 Broad Street, 31st Floor, New York, NY 10004, USA
    Curr Opin Pharmacol 6:459-67. 2006
  2. ncbi Mycobacterium tuberculosis DNA gyrase as a target for drug discovery
    Khisimuzi Mdluli
    Global Alliance for Tuberculosis Drug Development, 80 Broad Street, 31st Floor New York, NY 10004, USA
    Infect Disord Drug Targets 7:159-68. 2007
  3. ncbi Challenges and opportunities in developing novel drugs for TB
    Takushi Kaneko
    TB Alliance, 40 Wall Street, 24th Floor, New York, NY 10005, USA
    Future Med Chem 3:1373-400. 2011
  4. ncbi Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC
    Toni Kline
    Chiron Corporation, 201 Elliot Avenue West, Seattle, WA 98119, USA
    J Med Chem 45:3112-29. 2002

Collaborators

  • Zhenkun Ma
  • Takushi Kaneko
  • Toni Kline
  • Michael Doyle
  • Brian Mendelsohn
  • Susan Fong
  • Alex L Harris
  • Alice L Erwin
  • Andre Malanda
  • Pamela R Witte
  • Niels H Andersen
  • Asha Yabannavar
  • Shuguang Zhu
  • Jason Bowman
  • C Kendall Stover
  • Christian R H Raetz
  • Eric A Harwood
  • Stephanie Endsley

Detail Information

Publications4

  1. ncbi Novel targets for tuberculosis drug discovery
    Khisimuzi Mdluli
    Global Alliance for TB Drug Development, 80 Broad Street, 31st Floor, New York, NY 10004, USA
    Curr Opin Pharmacol 6:459-67. 2006
    ....
  2. ncbi Mycobacterium tuberculosis DNA gyrase as a target for drug discovery
    Khisimuzi Mdluli
    Global Alliance for Tuberculosis Drug Development, 80 Broad Street, 31st Floor New York, NY 10004, USA
    Infect Disord Drug Targets 7:159-68. 2007
    ..A novel inhibitor of M. tuberculosis DNA gyrase would be effective against multi-drug resistant (MDR)-TB, and it could also be effective against fluoroquinolone-resistant M. tuberculosis...
  3. ncbi Challenges and opportunities in developing novel drugs for TB
    Takushi Kaneko
    TB Alliance, 40 Wall Street, 24th Floor, New York, NY 10005, USA
    Future Med Chem 3:1373-400. 2011
    ..In this perspective we will focus on the early discovery phases of drug development and try to provide snapshots of both the current status and future prospects...
  4. ncbi Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC
    Toni Kline
    Chiron Corporation, 201 Elliot Avenue West, Seattle, WA 98119, USA
    J Med Chem 45:3112-29. 2002
    ..We now report the synthesis and in vitro evaluation of these P. aeruginosa LpxC inhibitors...